ERBB2 and breast cancer: T-DM1 has also been evaluated in other clinical trials such as MARIANNE, which compares the effectiveness of the taxanes (docetaxel or paclitaxel) combined with Herceptin vs T-DM1 by itself vs T-DM1 plus pertuzumab as a first line therapy for HER2+ breast cancers.